Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

Aptahem receives Turkish patent for the protection of patent family 2

09/29/2021 | 04:41am EST

Aptahem AB (publ) announces today that the Turkish patent office has approved the patent application as the first validated country in Europe. The patent was published with the patent number TR2021/013877 T4.

The approval by the Turkish patent office provides protection for the company's lead candidate Apta-1 within the patent family 2 in Turkey until 2037. The validation phase for the other specific countries where Aptahem has applied for patent protection is ongoing, with expected more approvals to come.

CEO Mikael Lindstam comments:

"I am very pleased to receive the final approval from the first of the European countries where we have applied for patent protection. Turkey is a country with many inhabitants and where we see a large long-term business potential."

For further information:

Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com

About Sepsis

Sepsis is today considered a world health problem and affects 49 million people worldwide each year, of which 11 million die. In Europe alone, over 1 million people are estimated to be affected by sepsis on a yearly basis*. There is currently no specific treatment for sepsis, but instead the underlying symptoms are treated with antibiotics, fluids and oxygen.

* Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, Colombara DV, Ikuta KS, Kissoon N, Finfer S, Fleischmann-Struzek C, Machado FR, Reinhart KK, Rowan K, Seymour CW, Watson RS, West TE, Marinho F, Hay SI, Lozano R, Lopez AD, Angus DC, Murray CJL, Naghavi M. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020 Jan 18;395(10219):200-211. doi: 10.1016/S0140-6736(19)32989-7. PMID: 31954465; PMCID: PMC6970225.

About Aptahem

Aptahem AB (APTA) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company's primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company possesses patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.



(c) 2021 Cision. All rights reserved., source Press Releases - English

Latest news "Companies"
07:51aNFON AG : Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
07:50aChevron Hits Production High in 2021, Net Output Down 5% in 4Q -- Energy Comment
07:50aCHEPLAPHARM AG : Timetable for the planned ipo is extended due to unfavorable market conditions
07:50aColgate-Palmolive Expects Earnings Growth This Year
07:49aVans owner cuts full-year revenue forecast on delivery delays
07:49aShare capital registered following acquisition of Kazang Zambia
07:48aMonrol Signing Agreement to License its GMP Grade Lu-177 n.c.a Production Technology to Curium
07:47aBORUSSIA DORTMUND GMBH & CO. KGAA : Notification and public disclosure of transactions by persons
07:46aSkål international usa inducts 2022 officers
07:46aSorenson Communications' SLi Approved as Official Provider for UK's New Emergency 999 Video Relay Service
Latest news "Companies"